Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance

Summary. In 100 untreated patients with chronic lymphocytic leukaemia (CLL) lymphocyte doubling time (LDT) has been investigated in relationship with clinical stages, bone marrow histological patterns, treatment‐free period and survival. Although partially correlated with clinical stages and bone marrow patterns. LDT has a clear prognostic significance by itself: whereas a LDT of 12 or less months identifies a population of patients with poor prognosis, a LDT higher than 12 months is indicative of good prognosis as substantiated by a long treatment‐free period and survival. This simple parameter can be useful in the clinical management of CLL patients.

[1]  E. Cronkite,et al.  Correlation of total body potassium and leukemic cell mass in patients with chronic lymphocytic leukemia. , 1979, Blood.

[2]  H. Theml,et al.  Management of CLL and allied disorders with reference to their immunology and proliferation kinetics. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[3]  D.,et al.  Regression Models and Life-Tables , 2022 .

[4]  E. Montserrat,et al.  Prognosis of chronic lymphocytic leukemia: a multivariate survival analysis of 150 cases , 1982 .

[5]  L. Zacharski,et al.  Chronic lymphocytic leukemia versus chronic lymphosarcoma cell leukemia. Analysis of 496 cases. , 1969, The American journal of medicine.

[6]  J. Frühling,et al.  Kinetics of lymphocytes in chronic lymphocytic leukemia. I. Equilibrium between blood and a "readily accessible pool". , 1973, Blood.

[7]  D. Catovsky,et al.  Prolymphocytic Leukaemia , 1974, British journal of haematology.

[8]  W. Dameshek.  Chronic Lymphocytic Leukemia—An Accumulative Disorder of Immunologically Incompetent Lymphocytes. , 1967 .

[9]  G. Brittinger,et al.  Die prognostische Relevanz der verschiedenen Stadieneinteilungen und der Lymphozytenverdopplungszeit bei der chronischen lymphatischen Leukämie , 1980 .

[10]  W. Dameshek.  Special Article: Chronic Lymphocytic Leukemia—an Accumulative Disease of Immunologically Incompetent Lymphocytes , 1967 .

[11]  L. Debusscher,et al.  Cell kinetics in chronic lymphocytic leukaemia (CLL). , 1977, Clinics in haematology.

[12]  E. Montserrat,et al.  Bone marrow biopsy in chronic lymphocytic leukaemia: a study of 208 cases. , 1983, Haematologia.

[13]  G. Cartwright,et al.  Factors influencing the duration of survival of patients with chronic lymphocytic leukemia. , 1966, The American journal of medicine.

[14]  B. Jakšić,et al.  Total Tumour Mass Score (TTM): a New Parameter in Chronic Lymphocytic Leukaemia , 1981, British journal of haematology.

[15]  E. Montserrat,et al.  Chronic Lymphocytic Leukaemia: Proposals for a Revised Prognostic Staging System , 1981 .

[16]  Karnolsky In.  Cytogenetic abnormalities in chronic lymphocytic leukemia. , 1984, The New England journal of medicine.

[17]  M. Gobbi,et al.  Staging of chronic lymphocytic leukemia. , 1982, Blood.

[18]  P. Dörmer,et al.  Chronic lymphocytic leukemia: a proliferative or accumulative disorder? , 1983, Leukemia research.

[19]  D. Cox.  Regression Models and Life-Tables , 1972 .

[20]  S. Perry,et al.  Studies of lymphocyte kinetics in man. , 1967, Blood.

[21]  Staging of chronic lymphocytic leukemia , 1982 .